Opendata, web and dolomites

FGFSTAB

Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FGFSTAB project word cloud

Explore the words cloud of the FGFSTAB project. It provides you a very rough idea of what is the project "FGFSTAB" about.

market    thermal    angiogenesis    fibroblast    wound    body    protein    healing    skin    trauma    dressings    slow    fgfs    technological    surgical    stress    play    limited    engineering    platform    optimization    primarily    good    greatest    sme    treatment    goes    clinical    authorization    half    commercial    industrial    stable    global    population    incidences    administrations    adverse    proteins    aging    organisms    expertise    close    fgf    hours    necessitating    biotechnological    diabetes    risk    therapy    gap    obesity    safe    poor    innovative    circulation    ulcers    practise    manufacturing    minutes    closes    world    cleared    started    medicine    heavily    fact    see    additional    financial    fgfstab    frequent    rising    effectiveness    demanding    marketing    homeostasis    life    natural    companies    course    despite    enantis    trials    chronic    investing    fireprot    regenerative    stability    instrument    care    embryonic    proprietary    lower    ageing    tissue   

Project "FGFSTAB" data sheet

The following table provides information about the project.

Coordinator
ENANTIS SRO 

Organization address
address: KAMENICE 771/34
city: BRNO
postcode: 625 00
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Project website https://www.enantis.com/fgfstab/
 Total cost 1˙030˙000 €
 EC max contribution 1˙030˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENANTIS SRO CZ (BRNO) coordinator 1˙030˙000.00

Map

 Project objective

The FGFSTAB project closes the gap between Enantis knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to the embryonic development, maintain tissue homeostasis, may slow down ageing of the organisms, and primarily promote angiogenesis and wound healing. FGFs see the greatest application in the care and treatment of chronic skin ulcers, but find use also in surgical and trauma wound healing. The global wound care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in current regenerative medicine and companies around the world have started investing heavily in research and development of growth factor-based products. However, despite clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability and a short half-life in the circulation; they are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment, which goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy. The key objective of the FGFSTAB project is to use an innovative technological platform, based on the application of Enantis proprietary protein optimization concept FireProt, to increase FGF stability under various stress conditions. Additional challenges including high cost of production, current Good Manufacturing Practise, development of delivery systems for safe and effective wound healing, and pre-clinical testing to support future clinical trials and marketing authorization, will be targeted as well. Financial support provided within SME Instrument phase 2 will help us to close the gap from demanding biotechnological development to the target industrial application in regenerative medicine.

 Deliverables

List of deliverables.
FGFSTAB web presentation Websites, patent fillings, videos etc. 2019-09-09 15:23:38

Take a look to the deliverables list in detail:  detailed list of FGFSTAB deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FGFSTAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FGFSTAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More